Home / Reports / Ranking and evaluation of quality attributes for biosimilarity

Ranking and evaluation of quality attributes for biosimilarity Posted 24/08/2018

Ranking and evaluation of quality attributes for biosimilarity was a subject discussed by Dr Patrick Lynch at the US Drug Information Association’s Biosimilars Conference [1].

According to Dr Lynch, considerations for ranking the criticality of an attribute include:

  • Primary mode of action
  • Biological activities involved in mechanism of action for each sought indication
  • Attributes that collectively contribute to biological activities (including impact on pharmacokinetics/pharmacodynamics and immunogenicity)
  • General properties of the molecule

The highest risk ranking attributes should be used to evaluate clinically relevant mechanism of action for each indication sought. However, it must be noted that some methods evaluate critical attributes, but generate data not amenable to rigorous statistical analyses, such as primary structure and higher order structure.

Dr Lynch gave an outline of the different approaches for statistical evaluation of critical attributes in Figure 1.

Figure 1: Approaches for statistical evaluation of critical attributes

CI: confidence interval; MoA: mechanism of action; PD: pharmacodynamics; PK: pharmacokinetics; SD: standard deviation.

In addition, attributes that may not be directly related to the primary mechanism of action, but act collectively to define the safety and efficacy profile of the reference product include:

  • Protein content (other than for products with a narrow therapeutic index or dosed on a linear curve)
  • Certain biological activities
  • complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), reverse signalling
  • Affinity to receptors or ligands
  • Glycosylation profile
  • Purity
  • Certain post-translational modifications that may affect activity

According to Dr Lynch, comprehensive assessment of critical attributes is an integral part of FDA’s totality‐of‐evidence approach to evaluate analytical similarity. This helps direct implementation of control strategies to address residual uncertainty when differences are identified.

Disclaimer
Dr Patrick Lynch, Product Quality Reviewer at the US Food and Drug Administration (FDA), stated that his presentation reflects the views of the author and should not be construed to represent FDA’s views or policies.

Related articles
Addressing uncertainty in biosimilarity

Lot selection and handling for biosimilarity

Analytical consideration in demonstrating similarity for biosimilars

Analytical similarity for biosimilars

Reference
1. Lynch P. Expectations and approaches for demonstrating analytical similarity. DIA Biosimilars Conference; 24-25 October 2017; Bethesda, Maryland, USA.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Comments (0)